BR112016007176A2 - conjugado, composição, usos de um conjugado e de uma composição, e, método para tratar um indivíduo que tem diabete - Google Patents
conjugado, composição, usos de um conjugado e de uma composição, e, método para tratar um indivíduo que tem diabeteInfo
- Publication number
- BR112016007176A2 BR112016007176A2 BR112016007176A BR112016007176A BR112016007176A2 BR 112016007176 A2 BR112016007176 A2 BR 112016007176A2 BR 112016007176 A BR112016007176 A BR 112016007176A BR 112016007176 A BR112016007176 A BR 112016007176A BR 112016007176 A2 BR112016007176 A2 BR 112016007176A2
- Authority
- BR
- Brazil
- Prior art keywords
- conjugate
- composition
- saccharide
- individual
- diabetes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
conjugados de insulina compreendendo uma molécula de insulina covalentemente ligada a pelo menos um ligador bidentado tendo duas ramificações, cada ramificação independentemente ligada a um ligante que compreende um sacarídeo e em que o sacarídeo para pelo menos um ligante do ligador é fucose são divulgados. os conjugados de insulina demonstram um perfil farmacocinético (pk) e/ou farmacodinâmico (pd) que é responsivo às concentrações sistêmicas de um sacarídeo tal como glicose ou alfa-metilmanose mesmo quando administrado a um indivíduo em necessidade do mesmo na ausência de uma molécula de ligação de sacarídeo multivalente exógena tal como con a.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361886717P | 2013-10-04 | 2013-10-04 | |
PCT/US2014/058714 WO2015051052A2 (en) | 2013-10-04 | 2014-10-02 | Glucose-responsive insulin conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016007176A2 true BR112016007176A2 (pt) | 2018-01-23 |
Family
ID=51794958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016007176A BR112016007176A2 (pt) | 2013-10-04 | 2014-10-02 | conjugado, composição, usos de um conjugado e de uma composição, e, método para tratar um indivíduo que tem diabete |
Country Status (13)
Country | Link |
---|---|
US (3) | US9884125B2 (pt) |
EP (1) | EP3052134B1 (pt) |
JP (1) | JP6491649B2 (pt) |
KR (1) | KR20160065930A (pt) |
CN (1) | CN105792852B (pt) |
AR (1) | AR097893A1 (pt) |
AU (1) | AU2014329567B2 (pt) |
BR (1) | BR112016007176A2 (pt) |
CA (1) | CA2924743A1 (pt) |
MX (1) | MX366852B (pt) |
RU (1) | RU2676307C2 (pt) |
TW (1) | TW201605470A (pt) |
WO (1) | WO2015051052A2 (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105753965A (zh) * | 2009-01-28 | 2016-07-13 | 斯马特塞尔斯公司 | 用于受控药物递送的基于缀合物的*** |
KR20160065930A (ko) | 2013-10-04 | 2016-06-09 | 머크 샤프 앤드 돔 코포레이션 | 글루코스-반응성 인슐린 접합체 |
MA39390B2 (fr) | 2014-03-21 | 2022-04-29 | Genzyme Corp | Thérapie génique pour le traitement de la rétinite pigmentaire |
CR20170208A (es) * | 2014-11-21 | 2017-07-17 | Merck Sharp & Dohme | Agonistas parciales del receptor de insulina |
EP3280450A4 (en) * | 2015-04-08 | 2018-12-12 | Merck Sharp & Dohme Corp. | Glucose-responsive insulin conjugates |
WO2016179568A1 (en) * | 2015-05-06 | 2016-11-10 | Protomer Technologies, Inc. | Glucose responsive insulins |
AR106364A1 (es) | 2015-08-25 | 2018-01-10 | Novo Nordisk As | Derivados de insulina y sus usos médicos |
WO2017124102A1 (en) | 2016-01-14 | 2017-07-20 | North Carolina State University | Glucose responsive insulin delivery compositions and methods |
WO2017205191A1 (en) * | 2016-05-24 | 2017-11-30 | Merck Sharp & Dohme Corp. | Insulin receptor partial agonists and glp-1 analogues |
WO2017207754A1 (en) * | 2016-06-02 | 2017-12-07 | Sanofi | Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein |
US20190365907A1 (en) * | 2017-01-17 | 2019-12-05 | Wayne State University | Zwitterionic polymer-insulin compositions and related methods |
EP3600381A4 (en) * | 2017-03-23 | 2021-06-16 | Merck Sharp & Dohme Corp. | GLUCOSE-ACTIVE INSULIN WITH A THREE-VALUE SUGAR CLUSTER FOR THE TREATMENT OF DIABETES |
US20180318426A1 (en) * | 2017-05-05 | 2018-11-08 | Merck Sharp & Dohme Corp. | Pharmaceutical formulations comprising insulin or insulin analogs conjugated to fucose for providing a basal pharmacodynamic profile |
WO2019034726A1 (en) | 2017-08-17 | 2019-02-21 | Novo Nordisk A/S | NOVEL ACYLATED INSULIN ANALOGUES AND USES THEREOF |
JP6874266B2 (ja) * | 2017-09-22 | 2021-05-19 | 国立研究開発法人日本原子力研究開発機構 | テトラアルキルニトリロ酢酸ジアセトアミド化合物の合成方法 |
WO2019075052A1 (en) * | 2017-10-10 | 2019-04-18 | North Carolina State University | INSULIN MODIFIED BY GLUCOSE TRANSPORTER INHIBITOR FOR GLUCOSE SENSITIVE INSULIN ADMINISTRATION |
KR20200095507A (ko) | 2017-12-01 | 2020-08-10 | 사노피 | 글루코오스 감지 단백질에 결합할 수 있는 모이어티 및 약제의 신규 접합체 |
EP3740212A4 (en) * | 2017-12-18 | 2021-10-27 | Merck Sharp & Dohme Corp. | CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY |
WO2019125878A1 (en) * | 2017-12-18 | 2019-06-27 | Merck Sharp & Dohme Corp. | Conjugate based systems for controlled insulin delivery |
EP3768291A4 (en) | 2018-03-22 | 2022-01-26 | Merck Sharp & Dohme Corp. | TYROSIN-SPECIFIC FUNCTIONALIZED INSULIN AND INSULIN ANALOGUES |
US20220233647A1 (en) * | 2019-06-06 | 2022-07-28 | Merck Sharp & Dohme Corp. | Glucose-responsive insulin conjugates |
WO2021021535A1 (en) * | 2019-07-30 | 2021-02-04 | Merck Sharp & Dohme Corp. | Glucose-responsive insulin conjugates |
US11498951B2 (en) | 2019-12-11 | 2022-11-15 | Novo Nordisk A/S | Insulin analogues and uses thereof |
WO2021209007A1 (en) * | 2020-04-15 | 2021-10-21 | Shenzhen Enduring Biotech, Ltd. | Antibody-drug conjugate |
CA3203332A1 (en) * | 2021-03-19 | 2022-09-22 | Yu WEN | Pegylated t cell engager with dual specificities to cd3 and cd19 |
WO2023091441A1 (en) * | 2021-11-22 | 2023-05-25 | Merck Sharp & Dohme Llc | Glucose-responsive insulin conjugates comprising a tetra-valent sugar cluster for treatment of diabetes |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3591574A (en) | 1968-05-29 | 1971-07-06 | American Home Prod | Tri-n-phenylglycyl derivatives of insulin |
DE1793517C3 (de) | 1968-09-28 | 1974-12-05 | Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt | N(Al),N(B29>Bis-(tert.-butyloxycarbonyl)-insulin und Verfahren zu seiner Herstellung |
US3847890A (en) | 1971-11-01 | 1974-11-12 | A Green | Acidic monosaccharide-substituted proteins |
US4086257A (en) | 1976-10-12 | 1978-04-25 | Sears Barry D | Phosphatidyl quaternary ammonium compounds |
US4377567A (en) | 1978-10-02 | 1983-03-22 | The Procter & Gamble Company | Lipid membrane drug delivery |
EP0009842B1 (en) | 1978-10-02 | 1982-11-10 | THE PROCTER & GAMBLE COMPANY | Liposomes for drug delivery and composition containing a liposome drug system |
US4348387A (en) | 1979-07-31 | 1982-09-07 | The Rockefeller University | Method and system for the controlled release of biologically active substances to a body fluid |
JPS608000B2 (ja) | 1980-04-11 | 1985-02-28 | 呉羽化学工業株式会社 | アミノフエニル誘導体及び該誘導体を含有する生理活性剤 |
US4444683A (en) | 1982-11-17 | 1984-04-24 | University Of Utah | Glycosylated insulin derivatives |
US4603044A (en) | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
EP0119650A3 (en) | 1983-03-21 | 1987-09-30 | THE PROCTER & GAMBLE COMPANY | Galactosyl-insulin conjugates useful in treating diabetics |
US4863896A (en) | 1984-05-03 | 1989-09-05 | Technology Unlimited, Inc. | Diabetic control by combined insulin forms |
US5239062A (en) | 1986-03-20 | 1993-08-24 | Dana-Farber Cancer Institute, Inc. | Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity |
US5395924A (en) | 1986-03-20 | 1995-03-07 | Dana-Farber Cancer Institute, Inc. | Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity |
US5527524A (en) | 1986-08-18 | 1996-06-18 | The Dow Chemical Company | Dense star polymer conjugates |
DK111489D0 (da) | 1989-03-08 | 1989-03-08 | Novo Nordisk As | Peptider |
AU628674B2 (en) | 1989-10-19 | 1992-09-17 | Nippon Oil And Fats Company, Limited | Polymer complexes of a sugar response type |
IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
US5304473A (en) | 1991-06-11 | 1994-04-19 | Eli Lilly And Company | A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production |
GB9200638D0 (en) | 1992-01-10 | 1992-03-11 | Leicester Polytechnic | Drug system |
DE69328523T2 (de) | 1992-02-13 | 2000-09-21 | Surmodics Inc | Immobilisierung eines chemischen spezies in einer vernetzten matrix |
GB9316895D0 (en) | 1993-08-13 | 1993-09-29 | Guy S And St Thomas Hospitals | Hepatoselective insulin analogues |
GB9313484D0 (en) | 1993-06-30 | 1993-08-11 | Univ Montfort | Drug system ii |
US6342225B1 (en) | 1993-08-13 | 2002-01-29 | Deutshces Wollforschungsinstitut | Pharmaceutical active conjugates |
US6869930B1 (en) | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
AU1272295A (en) | 1993-12-17 | 1995-07-03 | Novo Nordisk A/S | Proinsulin-like compounds |
US5461031A (en) | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
US6500645B1 (en) | 1994-06-17 | 2002-12-31 | Novo Nordisk A/S | N-terminally extended proteins expressed in yeast |
US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
IL118127A0 (en) | 1995-05-05 | 1996-09-12 | Lilly Co Eli | Single chain insulin with high bioactivity |
US5902603A (en) | 1995-09-14 | 1999-05-11 | Cygnus, Inc. | Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use |
TW520293B (en) | 1995-11-22 | 2003-02-11 | Univ Johns Hopkins Med | Delivery system to enhance cellular uptake of biomolecules |
US5723589A (en) | 1995-12-21 | 1998-03-03 | Icn Pharmaceuticals | Carbohydrate conjugated bio-active compounds |
US5948751A (en) | 1996-06-20 | 1999-09-07 | Novo Nordisk A/S | X14-mannitol |
US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
US5905140A (en) | 1996-07-11 | 1999-05-18 | Novo Nordisk A/S, Novo Alle | Selective acylation method |
JP2001527387A (ja) | 1997-01-24 | 2001-12-25 | ノボ ノルディスク アクティーゼルスカブ | 合成リーダーペプチド配列 |
ZA984697B (en) | 1997-06-13 | 1999-12-01 | Lilly Co Eli | Stable insulin formulations. |
ATE299889T1 (de) | 1998-04-15 | 2005-08-15 | Novo Nordisk As | Neues verfahren zur trennung von proteinen unter verwendung eines ca++ enthaltenden elutionsmittels |
US6844166B1 (en) | 1998-09-11 | 2005-01-18 | Sensor Technologies Inc. | Recombinant reduced valency carbohydrate binding ligands |
US6323311B1 (en) | 1999-09-22 | 2001-11-27 | University Of Utah Research Foundation | Synthesis of insulin derivatives |
US6521738B2 (en) | 1999-12-29 | 2003-02-18 | Novo Nordisk A/S | Method for making insulin precursors and insulin precursor analogs |
US6777207B2 (en) | 1999-12-29 | 2004-08-17 | Novo Nordisk A/S | Method for making insulin precursors and insulin precursor analogues having improved fermentation yield in yeast |
JP2003535106A (ja) | 2000-06-02 | 2003-11-25 | ノボ ノルディスク アクティーゼルスカブ | グルコース検知性インスリン誘導体からの、インスリンのグルコース依存性放出 |
US7316999B2 (en) | 2000-06-02 | 2008-01-08 | Novo Nordisk A/S | Glucose dependent release of insulin from glucose sensing insulin derivatives |
WO2002006789A2 (en) | 2000-07-13 | 2002-01-24 | The Ohio State University Research Foundation | Multimeric biopolymers as structural elements, sensors and actuators in microsystems |
KR100449454B1 (ko) | 2000-10-02 | 2004-09-21 | 이현철 | 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터 |
US7060675B2 (en) | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
US20020192182A1 (en) | 2001-03-12 | 2002-12-19 | Stephen Massia | Polysaccharide-based polymerizable hydrogels |
US7105314B2 (en) | 2001-04-02 | 2006-09-12 | Novo Nordisk A/S | Method for making human insulin precursors |
ES2516041T3 (es) | 2001-10-10 | 2014-10-30 | Ratiopharm Gmbh | Remodelación y glicoconjugación de la hormona del crecimiento humano (hGH) |
US7311892B2 (en) | 2001-10-26 | 2007-12-25 | The Uab Research Foundation | Multidrug multiligand conjugates for targeted drug delivery |
US7473680B2 (en) | 2001-11-28 | 2009-01-06 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
US7317000B2 (en) | 2001-12-02 | 2008-01-08 | Novo Nordisk A/S | Glucose-dependent insulins |
EP1452950A4 (en) | 2001-12-07 | 2009-07-08 | Ntt Docomo Inc | MOBILE COMMUNICATION SENDING DEVICE, METHOD FOR CONTROLLING THE PERFORMANCE OF AN APPLICATION PROGRAM, APPLICATION PROGRAM AND RECORDING MEDIA RECORDED FOR AN APPLICATION PROGRAM |
DE10209821A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
WO2004009666A2 (en) | 2002-07-19 | 2004-01-29 | The Regents Of The University Of California | Dendrimers as molecular translocators |
WO2004056311A2 (en) | 2002-12-17 | 2004-07-08 | Massachusetts Institute Of Technology | Stimuli-responsive systems for controlled drug delivery |
CA2549932C (en) | 2002-12-20 | 2013-08-20 | Greenovation Biotech Gmbh | Production of heterologous glycosylated proteins in bryophyte cells |
JPWO2004101619A1 (ja) | 2003-05-15 | 2006-10-26 | 塩野義製薬株式会社 | 機能的糖ペプチドの合理的設計および合成 |
JP5697831B2 (ja) | 2003-12-03 | 2015-04-08 | ノヴォ ノルディスク アー/エス | 単鎖インシュリン |
US20080102114A1 (en) | 2004-04-23 | 2008-05-01 | Panduranga Rao Koritala | Microparticles and Nanoparticles for the Transmucosal Delivery of Therapeutic and Diagnostic Agents |
WO2006008238A1 (en) | 2004-07-16 | 2006-01-26 | Novo Nordisk A/S | Method for selective acylation |
EP2626368B1 (en) | 2004-07-19 | 2016-12-21 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
WO2006062685A2 (en) | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
TWI376234B (en) | 2005-02-01 | 2012-11-11 | Msd Oss Bv | Conjugates of a polypeptide and an oligosaccharide |
US20070207498A1 (en) | 2005-02-24 | 2007-09-06 | Lifescan, Inc. | Design and construction of dimeric concanavalin a mutants |
US20060247154A1 (en) | 2005-02-24 | 2006-11-02 | Lifescan, Inc. | Concanavalin a, methods of expressing, purifying and characterizing concanavalina, and sensors including the same |
EP1863840A1 (en) | 2005-03-18 | 2007-12-12 | Novo Nordisk A/S | Pegylated single-chain insulin |
US7517856B2 (en) | 2005-10-11 | 2009-04-14 | Ben-Gurion University Of The Negev Research And Development Authority | Bioconjugates comprising sulfated polysaccharides and their uses |
WO2007047997A2 (en) | 2005-10-19 | 2007-04-26 | Smartcells, Inc. | Methods for reducing the mitogenicity of lectin compositions |
EP1991575A1 (en) | 2006-02-21 | 2008-11-19 | Novo Nordisk A/S | Single-chain insulin analogues and pharmaceutical formulations thereof |
JP5202338B2 (ja) | 2006-02-27 | 2013-06-05 | ノボ・ノルデイスク・エー/エス | 新規インシュリン誘導体 |
WO2007104734A1 (en) | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
WO2007104736A2 (en) | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
JP2009530243A (ja) | 2006-03-13 | 2009-08-27 | ノボ・ノルデイスク・エー/エス | アシル化単鎖インスリン |
EP1996223A1 (en) | 2006-03-13 | 2008-12-03 | Novo Nordisk A/S | Acylated single chain insulin |
WO2008036147A2 (en) | 2006-07-24 | 2008-03-27 | Duke University | Drug delivery with stimulus responsive biopolymers |
CN103169984B (zh) | 2006-07-25 | 2016-08-03 | 利普生技术有限公司 | N末端聚唾液酸化 |
FR2904315B1 (fr) | 2006-07-26 | 2012-12-14 | Centre Nat Rech Scient | Composes pyridaziniques et pyrroliques, procedes d'obtention et applications |
EP2054437A2 (en) | 2006-08-07 | 2009-05-06 | Teva Biopharmaceuticals USA, Inc. | Albumin-insulin fusion proteins |
CN101273961A (zh) | 2007-03-30 | 2008-10-01 | 中国人民解放军总医院 | 葡萄糖敏感水凝胶 |
US20090053167A1 (en) | 2007-05-14 | 2009-02-26 | Neose Technologies, Inc. | C-, S- and N-glycosylation of peptides |
WO2009033588A2 (en) | 2007-09-11 | 2009-03-19 | F. Hoffmann-La-Roche Ag | Self-controlled insulin delivery system |
WO2009059450A1 (en) | 2007-11-05 | 2009-05-14 | Shanghai Jiaotong University | Peptide ligand directed drug delivery |
JP5647899B2 (ja) | 2008-01-08 | 2015-01-07 | ラツィオファルム ゲーエムベーハーratiopharm GmbH | オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化 |
JP2011511778A (ja) | 2008-01-30 | 2011-04-14 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | エステルに基づいたペプチドプロドラッグ |
RU2381238C2 (ru) | 2008-01-31 | 2010-02-10 | Ордена Трудового Красного Знамени Институт нефтехимического синтеза им. А.В. Топчиева Российской академии наук (статус государственного учреждения) | Способ получения глюкозочувствительных полимерных гидрогелей |
KR101556514B1 (ko) | 2008-02-19 | 2015-10-02 | 바이오콘 리미티드 | 효모에서 발현된 정제된 이형 인슐린을 수득하는 방법 |
BRPI0911571A2 (pt) | 2008-04-22 | 2018-04-03 | Univ Case Western Reserve | método para tratar um mamífero, análogo de insulina, ácido nucléico e célula hospedeira |
WO2010008060A1 (ja) | 2008-07-17 | 2010-01-21 | 本田技研工業株式会社 | 車両用エアバッグとその製造方法 |
EP2376521B1 (en) | 2008-12-19 | 2016-04-13 | Indiana University Research and Technology Corporation | Amide-based insulin prodrugs |
EP2376099A4 (en) | 2008-12-19 | 2012-04-25 | Univ Indiana Res & Tech Corp | YL-BASED INSULIN-LIKE GROWTH FACTORS EXPRESSING HIGH ACTIVITY AT THE INSULIN RECEPTOR |
BRPI1007466A2 (pt) | 2009-01-28 | 2018-06-12 | Smartcells Inc | conjugado de insulina cristalina, formulação de liberação prolongada, e, sistema de distribuição de bomba |
WO2010088268A1 (en) | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Exogenously triggered controlled release materials and uses thereof |
JP2012516340A (ja) * | 2009-01-28 | 2012-07-19 | スマートセルズ・インコーポレイテツド | 合成コンジュゲートおよびその使用 |
US20110281792A1 (en) | 2009-01-28 | 2011-11-17 | Zion Todd C | Binding-site modified lectins and uses thereof |
JP2012516156A (ja) * | 2009-01-28 | 2012-07-19 | スマートセルズ・インコーポレイテツド | ポリヌクレオチドアプタマー系架橋物質体およびその使用 |
CN105753965A (zh) | 2009-01-28 | 2016-07-13 | 斯马特塞尔斯公司 | 用于受控药物递送的基于缀合物的*** |
EP2408808A4 (en) | 2009-03-20 | 2015-05-06 | Smartcells Inc | TERMINAL-FUNCTIONALIZED CONJUGATES AND THEIR USE |
US8569231B2 (en) | 2009-03-20 | 2013-10-29 | Smartcells, Inc. | Soluble non-depot insulin conjugates and uses thereof |
WO2011000823A1 (en) | 2009-06-30 | 2011-01-06 | Novo Nordisk A/S | Insulin derivatives |
CA2805739A1 (en) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Drug-ligand conjugates, synthesis thereof, and intermediates thereto |
AU2011282983A1 (en) | 2010-07-28 | 2013-02-21 | Smartcells, Inc. | Drug-ligand conjugates, synthesis thereof, and intermediates thereto |
AU2011282987A1 (en) | 2010-07-28 | 2013-02-21 | Smartcells, Inc. | Recombinant lectins, binding-site modified lectins and uses thereof |
WO2012050822A1 (en) * | 2010-10-14 | 2012-04-19 | Smartcells, Inc. | Uses of macrophage mannose receptor to screen compounds and uses of these compounds |
US8745838B2 (en) | 2011-06-23 | 2014-06-10 | Deere & Company | Ball joint assembly for attaching cutting unit to yoke |
AR087433A1 (es) * | 2011-08-08 | 2014-03-26 | Merck Sharp & Dohme | Analogos de insulina n-glicosilados |
KR20160065930A (ko) | 2013-10-04 | 2016-06-09 | 머크 샤프 앤드 돔 코포레이션 | 글루코스-반응성 인슐린 접합체 |
-
2014
- 2014-10-02 KR KR1020167011439A patent/KR20160065930A/ko not_active Application Discontinuation
- 2014-10-02 WO PCT/US2014/058714 patent/WO2015051052A2/en active Application Filing
- 2014-10-02 US US15/025,912 patent/US9884125B2/en active Active
- 2014-10-02 MX MX2016004259A patent/MX366852B/es active IP Right Grant
- 2014-10-02 US US14/504,476 patent/US9427475B2/en active Active
- 2014-10-02 EP EP14789446.3A patent/EP3052134B1/en active Active
- 2014-10-02 CA CA2924743A patent/CA2924743A1/en not_active Abandoned
- 2014-10-02 JP JP2016519370A patent/JP6491649B2/ja not_active Expired - Fee Related
- 2014-10-02 BR BR112016007176A patent/BR112016007176A2/pt not_active Application Discontinuation
- 2014-10-02 AR ARP140103669A patent/AR097893A1/es unknown
- 2014-10-02 CN CN201480066282.3A patent/CN105792852B/zh not_active Expired - Fee Related
- 2014-10-02 TW TW103134472A patent/TW201605470A/zh unknown
- 2014-10-02 RU RU2016116513A patent/RU2676307C2/ru active
- 2014-10-02 AU AU2014329567A patent/AU2014329567B2/en not_active Ceased
-
2016
- 2016-06-24 US US15/191,584 patent/US9889205B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
TW201605470A (zh) | 2016-02-16 |
AU2014329567B2 (en) | 2019-07-25 |
US20160303244A1 (en) | 2016-10-20 |
AU2014329567A1 (en) | 2016-04-07 |
RU2016116513A (ru) | 2017-11-09 |
KR20160065930A (ko) | 2016-06-09 |
JP2016533348A (ja) | 2016-10-27 |
MX2016004259A (es) | 2016-07-08 |
AR097893A1 (es) | 2016-04-20 |
JP6491649B2 (ja) | 2019-03-27 |
CN105792852B (zh) | 2019-12-10 |
US9427475B2 (en) | 2016-08-30 |
CA2924743A1 (en) | 2015-04-09 |
RU2676307C2 (ru) | 2018-12-27 |
RU2016116513A3 (pt) | 2018-06-28 |
US9884125B2 (en) | 2018-02-06 |
WO2015051052A2 (en) | 2015-04-09 |
US9889205B2 (en) | 2018-02-13 |
WO2015051052A3 (en) | 2015-07-02 |
US20160251407A1 (en) | 2016-09-01 |
CN105792852A (zh) | 2016-07-20 |
EP3052134B1 (en) | 2021-05-05 |
EP3052134A2 (en) | 2016-08-10 |
US20150105317A1 (en) | 2015-04-16 |
MX366852B (es) | 2019-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016007176A2 (pt) | conjugado, composição, usos de um conjugado e de uma composição, e, método para tratar um indivíduo que tem diabete | |
ZA202004099B (en) | Methylene carbamate linkers for use with targeted-drug conjugates | |
DOP2011000244A (es) | Sistemas basados en conjugados para entrega farmacologica controlada | |
BR112016009898A2 (pt) | células-tronco/progenitoras hematopoiéticas e efetoras não-t modificadas e usos das mesmas | |
BR112016016578A2 (pt) | Insulina de ação prolongada e uso daanálogo de insulina, polinucleotídeo, vetor de expressão, transformante, insulina de ação prolongada bem como seu método de preparação e formulação da mesma, conjugado, e uso do mesmo mesma | |
ECSP11011241A (es) | Sistemas basados en conjugados para entrega farmacológica controlada | |
NZ739250A (en) | Glucagon derivative and a composition comprising a long acting conjugate of the same | |
CL2015002940A1 (es) | Usos terapéuticos de empaglifozina. | |
BR112019000528A2 (pt) | distribuição mediada por ve de conjugados de proteína de ligação-molécula pequena | |
BR112015022585A2 (pt) | composto, uso de um composto, e, conjugado droga-anticorpo | |
CL2007001648A1 (es) | Compuesto derivado de leptomicina; conjugado que comprende agente de unión a células unido a uno o mas de dichos derivados; composiciones farmacéuticas que comprenden dicho derivado o conjugado; util en el tratamiento del cancer; proceso de preparacion de un compuesto o de un conjugado de un derivado de leptomicina. | |
BR112015015031A2 (pt) | processo de glicoconjugação | |
BR112016004242A8 (pt) | Métodos para conjugação sítio-específica de anticorpos e composições | |
NZ758050A (en) | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics | |
BR112015019985A2 (pt) | Novo análogo de insulina e sua utilização | |
BR112012026213A8 (pt) | Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa | |
AR092940A1 (es) | Metodos para el tratamiento del sindrome de alport | |
BR112015000310A2 (pt) | conjugado droga-molécula, e, método para inibir o esgotamento do tecido saudável durante a terapia com células t car | |
PA8790201A1 (es) | Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico | |
BR112015021470A2 (pt) | conjugado de polímero para administração de um agente bioativo | |
UY31543A1 (es) | Sistema de administracion de rnai de interferencia y usos del mismo | |
CL2008001124A1 (es) | Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer. | |
BR112015017246A2 (pt) | formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel | |
BR112017005985A2 (pt) | conjugado radiofarmacêutico | |
BR112017016503A2 (pt) | conjugado de fármaco de citotoxicidade-ligante, método de preparação para o mesmo, e aplicação para o mesmo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/00 (2006.01), A61P 3/10 (2006.01) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |